Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Healthcare
Biotechnology
1.20 $
+2.5%
vs. previous close
Closing price · As of: 3. Aug 2026
Telomir Pharmaceuticals, Inc. Common Stock (TELO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -3.7 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| -0.1 | -0.5 | -3.9 | -5.1 | -3.7 | |
| – | – | 1.6 | 4.3 | – | |
| – | – | 0.0 | 6.9 | 5.3 | |
| 0.0 | 0.4 | 0.1 | 0.1 | 0.6 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| – | 0.5 | 1.5 | -0.1 | 0.2 | |
| 0.1 | 0.5 | 3.9 | 6.3 | 9.7 | |
| 0.0 | 0.0 | 0.0 | 1.3 | 6.0 | |
| -0.1 | -0.5 | -3.9 | -5.1 | -3.7 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.